BASINGSTOKE, England and PHILADELPHIA, July 31 /PRNewswire/ -- Shire Limited (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the three months to June 30, 2008.
Q2 2008 Financial Highlights - Product sales up 40% to $706m - Product sales excluding ADDERALL XR(R) up 64% to $409m - New product sales(1) $243m, 34% of product sales (2007: 18%) - Total revenues up 35% to $776m - US GAAP earnings per ADS: loss $0.44 (2007: loss $9.93) - Non GAAP earnings per ADS up 70% to $0.95 (2007: $0.56) - Revenue guidance upgraded - 2008 revenue growth now expected to be at least 20% (previous guidance: mid to high teens) (1) New product sales comprise DAYTRANA, ELAPRASE, FOSRENOL, LIALDA / MEZAVANT and VYVANSE